Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2017 - 2026)

Axsome Therapeutics' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $73.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 18.61% year-over-year to $73.7 million; the TTM figure through Mar 2026 stood at $73.7 million (down 18.61% YoY), while the FY2025 annual figure was $77.5 million, down 15.42% from the prior year.
• Other Non-Current Liabilities came in at $73.7 million for Q1 2026 at Axsome Therapeutics, down from $77.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $91.7 million in Q4 2024 to a low of $27.4 million in Q3 2022.
• A 5-year average of $61.3 million and a median of $71.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 163.01% in 2024 and slipped 18.61% in 2026, its largest moves.
• Axsome Therapeutics' Other Non-Current Liabilities stood at $31.1 million in 2022, then surged by 135.69% to $73.3 million in 2023, then increased by 25.08% to $91.7 million in 2024, then retreated by 15.42% to $77.5 million in 2025, then retreated by 4.91% to $73.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $73.7 million, $77.5 million, and $89.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison